| Filed On | Filing |
|---|---|
| 04 Nov 2026 | 10-Q |
| 04 Nov 2026 |
8-K: Results of Operations and Financial Condition
ZUG, Switzerland, November 4, 2026 – MoonLake Immunotherapeutics (NASDAQ: MLTX) ("MoonLake" or the "Company"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today provided a bu... |
| 30 Sep 2026 |
8-K: Other Events
On September 30, 2026, MoonLake Immunotherapeutics (the “Company”) submitted a Biologics License Application (“BLA”) to the U.S. Food and Drug Administration (“FDA”), seeking approval of its tri-specific nanobody sonelokimab for the trea... |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 10 Aug 2026 | REGISTRATION STATEMENT |
| 10 Aug 2026 | REGISTRATION STATEMENT |
| 10 Aug 2026 | 10-Q |
| 10 Aug 2026 |
8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results |
| 29 Jul 2026 |
Form 4: Reich Kristian, Chief Scientific Officer
Sold 1,100 shares ($22K) |
| 23 Jul 2026 |
Form 4: Reich Kristian, Chief Scientific Officer
Sold 50,000 shares ($1M) · Sold 2,448 shares ($49K) |
| 21 Jul 2026 |
Form 4: Reich Kristian, Chief Scientific Officer
Sold 43,700 shares ($878K) |
| 20 Jul 2026 |
Form 4: Reich Kristian, Chief Scientific Officer
Sold 16,105 shares ($322K) |
| 15 Jul 2026 | 144 |
| 15 Jul 2026 |
8-K: Other Events
On July 10, 2026, the underwriters of the previously announced public offering of Class A ordinary shares, par value $0.0001 per share (the “Ordinary Shares”), of MoonLake Immunotherapeutics (the “Company”) and, in lieu of Ordinary Share... |
| 13 Jul 2026 |
Form 4: Santos da Silva Jorge, Director
Sold 33,936 shares ($679K) · Sold 68,289 shares ($1.37M) |
| 02 Jul 2026 |
Form 4: Santos da Silva Jorge, Director
Sold 47,775 shares ($957K) |
| 30 Jun 2026 | 144 |
| 29 Jun 2026 | SCHEDULE 13D/A |
Loading...